Rivastigmine
- Generic Name
- Rivastigmine
- Brand Names
- Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N2O2
- CAS Number
- 123441-03-2
- Unique Ingredient Identifier
- PKI06M3IW0
- Background
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
- Indication
For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
- Associated Conditions
- Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease
- Associated Therapies
- -
Comparative Research of Alzheimer's Disease Drugs
- Conditions
- Interventions
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 200
- Registration Number
- NCT01362686
- Locations
- 🇺🇸
Touchpoint, Fishers, Indiana, United States
🇺🇸Methodist Center for Geriatric Medicine, Indianapolis, Indiana, United States
🇺🇸University Clinical Neurology, Indianapolis, Indiana, United States
Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study
- Conditions
- Interventions
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Target Recruit Count
- 33
- Registration Number
- NCT01348282
- Locations
- 🇪🇸
Fundació LLuita contra la SIDA, Badalona, Barcelona, Spain
Cognitive Decline in Non-demented PD
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 9
- Registration Number
- NCT01340885
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2010-08-18
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- Federal University of Bahia
- Target Recruit Count
- 40
- Registration Number
- NCT01183806
- Locations
- 🇧🇷
Ferderal University of Bahia - DINEP, Salvador, Bahia, Brazil
🇧🇷Federal University of Bahia, Salvador, Bahia, Brazil
Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 44
- Registration Number
- NCT01146067
Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2010-06-17
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 44
- Registration Number
- NCT01146041
Rivastigmine Study in Adolescents With Down Syndrome
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- Duke University
- Target Recruit Count
- 42
- Registration Number
- NCT01084135
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
Rivastigmine as a Treatment for Methamphetamine Dependence
- Conditions
- Interventions
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT01073319
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States
Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia
- Conditions
- Interventions
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2012-04-24
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 40
- Registration Number
- NCT00767091
- Locations
- 🇫🇷
Devos, Lille, Nord, France
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 49
- Registration Number
- NCT00766363
- Locations
- 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
🇺🇸Global Medical Institutes, LLC, Princeton, New Jersey, United States
🇺🇸Pacific Research Network, Inc., San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.